PMID- 27660429
OWN - NLM
STAT- Publisher
LR  - 20220409
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 11
DP  - 2016
TI  - Inflammatory biomarkers in asthma-COPD overlap syndrome.
PG  - 2117-2123
AB  - BACKGROUND: The clinical phenotypes and underlying mechanisms of asthma-COPD 
      overlap syndrome (ACOS) remain elusive. This study aimed to investigate a 
      comparison of COPD patients with and without ACOS, focusing on inflammatory 
      biomarkers, in an outpatient COPD cohort. METHODS: We conducted a cross-sectional 
      study analyzing prospectively collected data from the Ishinomaki COPD Network 
      registry. All participants were diagnosed with COPD, confirmed by using 
      spirometry, and were aged 40-90 years and former smokers. Patients with features 
      of asthma including both variable respiratory symptoms and variable expiratory 
      airflow limitation were identified and defined as having ACOS. Then, the 
      inflammatory biomarkers such as fractional exhaled nitric oxide level, blood 
      eosinophil count and percentage, total immunoglobulin E (IgE) level, and presence 
      of antigen-specific IgE were evaluated. RESULTS: A total of 257 patients with 
      COPD were identified, including 37 (14.4%) with ACOS. Patients with ACOS tended 
      to be younger, have a shorter smoking history, and use more respiratory 
      medications, especially inhaled corticosteroids and theophylline. Mean fractional 
      exhaled nitric oxide level was significantly higher in those with ACOS than in 
      those without ACOS (38.5 parts per billion [ppb] vs 20.3 ppb, P<0.001). Blood 
      eosinophil count and percentage were significantly increased in those with ACOS 
      (295/mm(3) vs 212/mm(3), P=0.032; 4.7% vs 3.2%, P=0.003, respectively). Total IgE 
      level was also significantly higher, and presence of antigen-specific IgE was 
      observed more frequently in patients with ACOS. Receiver operating characteristic 
      curve analysis indicated that the sensitivity and specificity of these biomarkers 
      were relatively low, but combinations of these biomarkers showed high specificity 
      for ACOS diagnosis. CONCLUSION: These results provide evidence that these 
      inflammatory biomarkers can be used to support the diagnosis of ACOS.
FAU - Kobayashi, Seiichi
AU  - Kobayashi S
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan.
FAU - Hanagama, Masakazu
AU  - Hanagama M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan.
FAU - Yamanda, Shinsuke
AU  - Yamanda S
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan.
FAU - Ishida, Masatsugu
AU  - Ishida M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan.
FAU - Yanai, Masaru
AU  - Yanai M
AD  - Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160907
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
PMC - PMC5021052
OTO - NOTNLM
OT  - COPD
OT  - asthma
OT  - asthma-COPD overlap syndrome
OT  - biomarkers
EDAT- 2016/09/24 06:00
MHDA- 2016/09/24 06:00
PMCR- 2016/09/07
CRDT- 2016/09/24 06:00
PHST- 2016/09/24 06:00 [entrez]
PHST- 2016/09/24 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
PHST- 2016/09/07 00:00 [pmc-release]
AID - copd-11-2117 [pii]
AID - 10.2147/COPD.S113647 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2016 Sep 7;11:2117-2123. doi: 
      10.2147/COPD.S113647. eCollection 2016.